Sorry, you need to enable JavaScript to visit this website.

Study Investigating the Safety and Tolerability of Different Doses of Crizotinib in Participants with Advanced Cancers.

Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, a MET/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer

Category & Conditions: Cancer
Medicine: XALKORI®(CRIZOTINIB) Identifier (NCT): NCT00585195
Protocol ID: A8081001
Open Plain Language Summary Result: Click here